Skip to content

MISOPROSTOL BY SUBLINGUAL ROUTE IN ADDITION TO standard OXYTOCIN injection TO REDUCE BLOOD LOSS DURING AND AFTER CESAREAN DELIVERY IN WOMEN prone to EXCESSIVE BLOOD LOSS.

400 microgram MISOPROSTOL BY SUBLINGUAL ROUTE IN ADDITION TO OXYTOCIN TO REDUCE INTRAOPERATIVE AND POST OPERATIVE BLOOD LOSS DURING CESAREAN DELIVERY IN HIGH RISK WOMEN.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/05/003645
Enrollment
100
Registered
2013-05-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- WOMEN WITH ONE OR MORE OF RISK FACTORS FOR PPH UNDERGOING CESAREAN SECTION.

Interventions

Intervention1: misoprostol and oxytocin: study group will receive 400microgram of misoprostol sublingually along with oxytocin 10units intramuscular and 10 units in iv drip. Control Intervention1: pla

Sponsors

NRS MEDICAL COLLEGEKOLKATA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women undergoing Cesarean section having one or more of the following high risk factors will be enrolled â?? Multiple pregnancy Polyhydramnios foetal macrosomia(more than 4 kg) prolonged / obstructed labor( as per standard guideline after partographic monitoring) H/O PPH in previous delivery Obese patient (BMI >30) Grand multipara APH Anaemic women (Hb less than 10gm/dl.)

Exclusion criteria

Exclusion criteria: Any contraindications for the use of misoprostol and oxytocin such as known hypersensitivity, asthma, epilepsy , Cardiovascular, hepatic, haematological disorder, Temperature >38ï?°C

Design outcomes

Primary

MeasureTime frame
1. introperative and postoperative blood loss ( 4 hours) . 2. drop of haemoglobin and haematocrit post delivery at 24 hours. Timepoint: 1. introperative and postoperative blood loss ( 4 hours) . 2. drop of haemoglobin and haematocrit post delivery at 24 hours.

Secondary

MeasureTime frame
i) Need for blood transfusion . ii) Need of additional uterotonic . iii) Side effects and complications. Timepoint: 24 HOURS

Countries

India

Contacts

Public ContactDR PICKLU CHAUDHURI

N.R.S MEDICAL COLLEGE,KOLKATA

picklu.chaudhuri@gmail.com9432277443

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 7, 2026